Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer

doi:10.3748/wjg.v18.i12.1357

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 12

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3793)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

364

HTML

2972

Figures (1-2)

247

Tables (1-6)

210

Sum=3793

Mar 28, 2012 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Mar 28, 2012; 18(12): 1357-1364
Published online Mar 28, 2012. doi: 10.3748/wjg.v18.i12.1357

Open in New Tab Full Size Figure Download Figure

Figure 1 Survival from the start of second-line therapy. A: Overall survival; B: Progression-free survival.

Open in New Tab Full Size Figure Download Figure

Figure 2 Overall survival and carbohydrate antigen 19-9 evolution in second line. A: Overall surviva; B: Progression-free survival. Ev. Ca 19-9: Course of carbohydrate antigen 19-9.

Citation: Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364
URL: https://www.wjgnet.com/1007-9327/full/v18/i12/1357.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i12.1357